ADDYI (Flibanserin) Patent Expiration, LOE Window & CMS Spending

ADDYI (Flibanserin) by Sprout: FDA Orange Book LOE 2028-12-13, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSprout
FDA Application & PathwayN022526 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-12-13
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 141.1% 2-yr change)